aibio
Listings ·
CytoMed Therapeutics gets Nasdaq bid price notice, has until April 5, 2027
Nasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.
GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics (GDTC) news
Latest CytoMed Therapeutics news
We have not published a story on CytoMed Therapeutics yet. When there is news, it will appear here.
What CytoMed Therapeutics does
CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company developing cell-based immunotherapies for human cancers and degenerative diseases. It has two platform technologies for off-the-shelf cell-based cancer immunotherapies that do not depend on a patient's own blood cells, one using healthy donor blood cells and the other using induced pluripotent stem cells, known as iPSC. The company says the products exploit the multiple antigen recognition systems of NK cells and gamma delta T cells to target a broad range of cancers, including solid tumors where CAR-T therapy has limits. It is developing four cellular immunotherapy candidates. Its lead candidate, CTM-N2D, is being evaluated in the ANGELICA Trial, which National University Hospital Singapore conducts, with CytoMed supplying the product at no cost. The trial has received co-funding from MOH Singapore through the National Medical Research Council. Patient recruitment began in November 2024, and the company anticipates recruiting more patients in 2026. CytoMed is incorporated in Singapore and conducts its business mainly through subsidiaries in Malaysia.
| Product or program | What it is | Stage |
|---|---|---|
| CTM-N2D | Lead candidate: expanded gamma delta T cells grafted with an NKG2DL-targeting CAR | in clinical trial (ANGELICA Trial), dose level 2 ongoing |
| iPSC-gdNKT | Synthetic hybrid of gamma delta T and NK cells made from iPSC | pre-clinical process development |
| CTM-GDT | Expanded allogeneic gamma delta T cells for a broad range of cancers | preclinical |
| CTM-NK | Fourth cellular immunotherapy candidate in the pipeline |
CytoMed Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $252,265 | $50,872 |
| Research and development | $1.7 million | $1.4 million |
| Net income (loss) | -$3.1 million | -$1.8 million |
| Cash from operations | -$2.9 million | -$2.0 million |
| Cash and equivalents | $1.6 million | $3.7 million |
Questions about CytoMed Therapeutics
What is the ticker symbol of CytoMed Therapeutics?
CytoMed Therapeutics Limited trades under the ticker GDTC on NASDAQ.
Where is CytoMed Therapeutics listed?
CytoMed Therapeutics Limited is listed on NASDAQ.
What is the SEC CIK of CytoMed Therapeutics?
The SEC Central Index Key (CIK) for CytoMed Therapeutics Limited is 1873093. Its filings are on SEC EDGAR.
How many shares does CytoMed Therapeutics have outstanding?
11,828,435 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.
Which country or territory is CytoMed Therapeutics listed under?
Our directory records CytoMed Therapeutics Limited under Singapore.
What does CytoMed Therapeutics do?
Our directory classifies CytoMed Therapeutics Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of CytoMed Therapeutics?
The ISIN recorded for CytoMed Therapeutics Limited is SGXZ17669631.
Does aibio.space cover CytoMed Therapeutics?
aibio.space lists CytoMed Therapeutics Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Where is CytoMed Therapeutics incorporated?
SEC records list its state or country of incorporation as U0.
What does CytoMed Therapeutics develop?
CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company developing cell-based immunotherapies for human cancers and degenerative diseases. It has two platform technologies for off-the-shelf cell-based cancer immunotherapies that do not depend on a patient's own blood cells, one using healthy donor blood cells and the other using induced pluripotent stem cells, known as iPSC.
What is CTM-N2D from CytoMed Therapeutics?
CTM-N2D: Lead candidate: expanded gamma delta T cells grafted with an NKG2DL-targeting CAR Stage: in clinical trial (ANGELICA Trial), dose level 2 ongoing.
What is iPSC-gdNKT from CytoMed Therapeutics?
iPSC-gdNKT: Synthetic hybrid of gamma delta T and NK cells made from iPSC Stage: pre-clinical process development.
What was CytoMed Therapeutics's revenue last year?
$252,265 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is CytoMed Therapeutics profitable?
CytoMed Therapeutics Limited reported a net loss of $3.1 million for the fiscal year ended Dec 31, 2025, and used $2.9 million of cash in operations, per its annual report to the SEC.
How much does CytoMed Therapeutics spend on research and development?
$1.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: CytoMed Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- CytoMed Therapeutics Ltd
- CIK
- 1873093
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- GDTC (Nasdaq)
- State or country of incorporation
- U0
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Business address
- #08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore, 149544
- Phone
- 603824911
- Shares outstanding
- 11,828,435 as of 2025-12-31 (20-F filed 2026-03-31)
- Former names
- CytoMed Therapeutics Pte. Ltd.
Recent filings
Listing details
- Company
- CytoMed Therapeutics Limited
- Ticker
- GDTC
- Listing
- NASDAQ
- Country or territory
- Singapore
- Business scope
- Biotechnology
- ISIN
- SGXZ17669631
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction